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Abstract 
Research on alternatives to the use of animal models and cell cultures has led to the creation of organ-on-
a-chip systems, in which organs and their physiological reactions to the presence of external stimuli are 
simulated. These systems could even replace the use of human beings as subjects for the study of drugs in 
clinical phases and have an impact on personalized therapies. Organ-on-a-chip technology present higher 
potential than traditional cell cultures for an appropriate prediction of functional impairments, appearance 
of adverse effects, the pharmacokinetic and toxicological profile and the efficacy of a drug. This potential is 
given by the possibility of placing different cell lines in a three-dimensional-arranged polymer piece and 
simulating and controlling specific conditions. Thus, the normal functioning of an organ, tissue, barrier, or 
physiological phenomenon can be simulated, as well as the interrelation between different systems. 
Furthermore, this alternative allows the study of physiological and pathophysiological processes. Its design 
combines different disciplines such as materials engineering, cell cultures, microfluidics and physiology, 
among others. This work presents the main considerations of OoC systems, the materials, methods and 
cell lines used for their design, and the conditions required for their proper functioning. Examples of 
applications and main challenges for the development of more robust systems are shown. This non-
systematic review is intended to be a reference framework that facilitates research focused on the 
development of new OoC systems, as well as their use as alternatives in pharmacological, pharmacokinetic 
and toxicological studies.  
©2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
The development of new drugs is an expensive process that presents several challenges in  preclinical 
and clinical studies [1,2], where a 59 % of the medicines that initiate a clinical study go into phase II, just a 
21 % starts phase III, and merely a 10 % reach approval by the regulatory authority. The appearance of 
adverse effects is one of the main reasons for drug failure, becoming one of the biggest challenges and 
weaknesses presented by preclinical models as predictors of clinical performance [2–5]. However, clinical 
failures are not just the result of safety-related situations, but are also linked to the lack of clinical efficacy 
[6]. The non-detection of side effects can also become an issue for a drug that has already passed the 
clinical phase. The non-adequate determination of adverse effects can lead to market recalls. These 
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unwanted events are mainly liver- or heart-related, due to the effect of metabolite generation [5,7]. 
Animal models applied in preclinical phases are often unrepresentative to the human body, thus failing 
in the prediction of the efficacy and safety of drugs [1,3,4,8,9]. However, clinical failures might be mitigated 
by adding models with a superior predictor capacity in preclinical phases [10]. The use of traditional two-
dimensional (2D) cell cultures has made great contributions to medicine so far, and it has led to reduce the 
use of laboratory animals. However, these systems do not allow the study of tissue’s microenvironment or 
the complex interrelationships between different tissues and organs of the human body. Moreover, the 
study of isolated cells without a systematic functional evaluation presents the risk of ignoring structural 
alterations that may have an impact on the organ’s function, even if those isolated cells remained viable 
[1,10].  
In recent years, the Organ-on-a-Chip (OoC) technology has emerged as an alternative in drug 
development, as it aims to reflect the environmental, functional, and interrelationship characteristics of 
organs and tissues [2,11]. The concept of reproducing organic and physiological functions of the human 
body by using cells within a microfluidic chip was first published in 2004, when Shuler et al. showed a cell 
culture that exemplified the interaction between the lung and the liver on a square-inch silicone chip. The 
term Organ-on-a-Chip was adopted in 2010 [2,7,12,13]. 
Compared with traditional models, this technique provides improved information about cells 
mechanical properties, morphology, and differentiation, among others. OoC improve the determination of 
cell responses, genetic expressions, and cell function. These systems can have an impact on the candidates 
selection and evaluation for the development of new medicines, as they allow gaining information about 
metabolites secretion performed by certain cells when interacting with drugs [1]. Furthermore, OoC have 
the potential to reduce and supplement the use of animals, cell models, and even humans in new drugs 
development [7].  
OoC systems offer a better understanding of pathophysiology, allowing new drugs design into specific 
mechanisms and promote therapeutic development for pathologies such as cancer, neurological disorders, 
and orphan diseases [2]. Choi et al. used a tridimensional (3D) cancer model for the selection of a most 
effective drug against lung cancer cells [14]. Liu et al. studied brain metastasis with a multi-organ chip that 
showed functional barrier characteristics [15]. During the COVID-19 pandemic caused by the SARS-CoV-2 in 
2020, and in the middle of a global race to slow down the progression of the disease, OoCs were applied in 
the research for treatments with fast and reliable results on the preclinical scale [16]. 
The development of these models brought to the emergence of an industry with more than 28 
companies  founded in 7 years [7,17,18]. Hundreds of publications are generated each year regarding this 
topic, which rises the interest of companies carrying out basic research in the field of drugs and also in 
other areas such as cosmetics, food and medical devices [8,11,19–22].  
Some of the synonyms under which OoC can be found in the literature are the following ones: lab-on-a-
chip [17], organoids-on-chip [23], organ-on-a-plate[6], tissue-on-chip [9], microphysiological system 
(MPS)[6], and MPS-based organ model [24]. This work is intended to be a reference framework that 
facilitates research focused on the development of new OoC systems, as well as their use as alternative in 
pharmacological, pharmacokinetic and toxicological studies with the aim of making them become a more 
powerful, accurate and used research tool in drug development. 
OoC basic features 
This field of study emerges as a combination of cellular biology, cell culture engineering, microsystem 
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engineering, microfluidic studies, and materials engineering. This complexity of disciplines allows to create 
microenvironments with precise mechanical, and structural control, providing the ability to recreate 
concentration gradients, and nutrients and metabolites flows [2,3,7,25–31]. Therefore, they are versatile 
and modifiable systems with the aim of showing an adequate histological composition that is suitable for 
live evaluation, which cannot be done by using animal models [32]. 
As an interdisciplinary field, a broader understanding of the OoC technology requires knowledge in each 
of the sciences that are part of it. Since the evolution of these devices involves technology advances in each 
of these areas, it faces the same difficulties as they do [18], especially with the objective of mass 
production and sustainable implementation of OoC. Some of these challenges are discussed later in this 
document, although the authors recommend a further study of the basic principles and state of the art of 
the abovementioned scientific fields. Detailed reviews focused on each of these research areas can be 
consulted elsewhere [33–41]. 
The spatial configuration of each OoC depends on its design and desired function, however, most of 
them show the general outlines presented in Figure 1; they are constituted by a physical compartment for 
cell confinement and several microfluidic channels, which are used for the administration and transport of 
substances and measurable signals. In their integrated compartment OoCs allow to study, measure and 
control cell behavior, as well as the response of the target tissue microenvironment in front of certain 
stimuli [2]. It is also possible to integrate secondary tissues in the OoC, which cannot be performed in 
traditional cellular models [5]. 
The OoC can reproduce particular conditions, such as the presence of specific pathologies, age and sex 
differences, or metabolic modifications [3,7,8,15,42–44]. The ability of OoC systems to mimic the 
functionality of an organ allows to visualize the impact of a condition on the organ’s function. For example, 
for the study of a viral infection at kidney level, a traditional 2D culture would be able to demonstrate the 
virus replication but its impact on the kidney’s function would not be proved unless the 2D culture was 
coupled to an OoC system capable of mimicking glomerular filtration [45]. 
 
Figure 1. Examples of OoC devices. A) Three-layer chip with a cell culture receptacle on the bottom plate, and 
multiple channel connectors for feed and signal control on the top plate. Adapted from [46] with permission 
from The Royal Society of Chemistry. Copyright (2018) B) A Two-channel OoC for the simulation of an 
epithelial tissue. Reproduced from [47] under terms of the Creative Commons Attribution License. C) OoC 
model for the simulation of the blood-brain barrier with gel suspended astrocytes and neurons. Reproduced 
from [48] with permission from The Royal Society of Chemistry. Copyright (2017). 
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OoC systems are intended to be a useful tool to reduce the number of false positives and false negatives 
in the preclinical evaluation of potential drug prototypes. Therefore, they might be able to raise the 
number of candidates that successfully complete clinical trials [6]. Moreover, these systems have fewer 
ethical or animal welfare concerns than traditional animal models [49,50]. OoC can facilitate the design and 
validation of drugs that aim specific cellular and molecular targets [18,44], and could be used to establish 
the pharmacokinetic profile of drugs [51]. Table 1 shows some of the main characteristics of existing 
preclinical models for a comparative benefits-drawbacks evaluation. 
Table 1. Main comparative characteristics of traditional preclinical evaluation models and OoC. 
Modified from [5]. 
Characteristics Animal 2D OoC 
Target tissue’s representativeness Low Low High 
Ethical implications Medium Low Low 
Associated costs High Low Low 
Viability maintenance  Medium High High 
High throughput analysis aptitude Low High Medium 
Full body representativeness High Low Medium 
OoC functional characteristics 
The design of OoC involves reverse engineering of living organs [42,52], which requires an in-depth 
study of the organs and their functions to develop systems more physiologically relevant than current in 
vitro models. This has promoted the physio-pathological study of multi-organ interrelationships 
[31,42,44,49,53]. The main benefits of OoC arise from their ability to mimic three key organ aspects in their 
physiological function [7,54], which are: 
1. Interfaces that present barrier functions composed of multiple tissues and vasculature. 
2. Organization at a parenchymal level (i.e. the presence of different tissue substructures within the 
same organ). 
3. The interaction between different organs. 
Additionally, to be adaptable to HTS, OoC systems require the incorporation of sensors and 
communication channels [7,27,28] for real-time data collection and analysis [42]. 
Reproduction of barrier or interface properties 
Non-homogeneous cell mixtures contain variations in shape, arrangement and interaction through 
interfaces of different cells, which limits the use of 2D cell cultures [7]. Traditionally, epithelia used to be 
reproduced in vitro as several cell layers on a surface. However, the evolution of OoC production systems, 
and the ability to diversify 3D structures, allow a more accurate correspondence with the physiological and 
anatomic-functional conditions of epithelial barriers [47]. OoC microfluidic channels can incorporate 
polymeric membranes to model tissue interfaces, simulate barrier properties and, in some cases, they can 
even include programmed mechanical instruments [7,50,55]. 
The possibility of establishing a 3D vascular structure enables to extend the complexity and 
representativeness of the systems mimicked in an OoC. This is especially valuable with regard to the 
targeting of nutrients and exogenous substances if compared to 2D tissues, where transport occurs by 
simple diffusion [55]. Furthermore, OoCs have the ability to include dynamic factors that simulate complex 
biological events [7,56]. 
On one hand, the simulation of the physiological interface can be performed  in the chip’s primary 
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physical structure itself or by controlling the mobility of hydrogels through the channels of this polymeric 
structure [7]. Current printing techniques allow complex 3D structures to simulate vascularized tissues and 
to modulate permeability through the creation of nano-porosities [7,42,57,58]. Therefore, it is possible to 
provide mechanical stability to functional cell cultures and to generate a network designed for the 
transport of substances and to simulate specific desired (even pathogenic) organ-organ interaction 
conditions [7,26]. On the other hand, the use of hydrogels (e.g. gelatine, fibrin or collagen) within the chip 
channels generates hydrophilic networks that provide the system with slight selective permeability 
[43,59,60]. The mimicking of several epithelial structures such as blood vessels, alveoli and the blood-brain 
barrier have been achieved by using OoCs [61]. 
Reproduction of parenchymal tissue  
In a living organism, cells are specifically organized according to tissue’s function [2,7,43,62]. The 
arrangement of these cells is one of the main features to consider for the physiological simulation outside 
the native environment [8,31,42,63]. While membranes and barriers can be simulated in both 2D and 3D 
cultures, complex parenchymal structures cannot be mimicked in a 2D culture [1,7,8,28,43,63]. 
Furthermore, gene expression of cells has been observed to be greater in 3D tissues compared to 2D cell 
cultures [64]. 
Considering two models of cardiotoxicity assessment, an in vitro 2D model enables the evaluation of the 
cardiomyocytes viability in the presence of a drug but it cannot assess the functionality of the cells. 
Nevertheless, the effect that this drug may produce in the contraction capacity of cardiomyocytes could be 
observed by using a 3D arrangement. An adverse reaction, such as arrhythmia, might not be detected in the 
2D model and would become a potential issue on further clinical phases, but it could be noticed employing 
an OoC that evaluates changes in the 3D accommodation and the proper functionality of the organ [44,65]. 
Reproduction of the interaction between organs 
Living tissues are highly integrated, they are not isolated, in such a way that the effects in one tissue can 
impact other tissues [66]. Intercommunication between different organs plays an important role in the 
safety of a drug and, thus, in the cost-benefit ratio of the clinical studies [42]. This inter-organ 
communication is absent in most traditional cell cultures, however, OoCs allow the coupling of different 
organs according to their physiological disposition [42,44,51], either on a chip with different cavities or by 
interconnecting different chips [7,42], as shown in Figure 2. The mimicking of this organ-organ interaction 
in OoC leads to better evaluations of absorption and metabolism [10,51]. Therefore, these systems enable 
to observe how the organs are affected by the main compound and by the metabolites that might be 
generated under physiological conditions [11,67,68]. 
Multicellular tissues and structures in living organs experience mechanical forces such as blood flow, 
compression, and tension, that are important for physiological processes [42,44,70,71]. Blood flow is critical 
for cells maturation and differentiation, as well as for their proper functioning [55,70]. OoC devices enable 
the reproduction of some forces by modulating the flow characteristics [42,70]. This can be performed by 
passive manners, when talking of gravity or concentration gradient, or actively, through the integration of 
micro-pumps together with their respective control and measurement systems [44,54,72,73]. Good 
simulations of cell migration from one tissue to another, as can be immune cells,  or cancer cells in 
methasteses, are important challenges [7]. Sophisticated microenvironments can also be mimicked by using 
multilayer technologies, parallel microchannels, cellular spheroids, turning devices, or varying the cellular 
arrangement pattern, among others [30]. The integration of the support and channel architectures, the 3D 
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cell arrangement and the flow systems enable the appropriate nutrients supply, the waste elimination and 
the exchange of molecular and analytical signals [13,49,50,52,58,74]. 
 
Figure 2. Organ interaction in OoC. A) Schematic representation of miniaturized digestive system. B) Heart–
liver body-on-a-chip with a liver module, cardiomyocytes and a skin module on a single chip. C) Body-on-a-
chip simulation with gastrointestinal tract and liver tissue with two coupled chips. Adapted respectively from 
[69], [67], and [68] with permission from The Royal Society of Chemistry. Copyright (2019, 2020 & 2014) 
Measurement systems integration 
Although several analytical methods can be coupled to OoC (see Table 2 for some examples), these 
systems still show lower capacity to adapt to HTS than 2D tissues. OoC will, however, present a higher 
adaptability as soon as faster and more reliable analytical systems are developed for on-line analysis 
[4,13,62,71,75]. 
Table 2. Main analytical techniques reported for on-line analysis of OoC. 
Analytical technique References 
Fluorescence [24,53,76,77][78] 
Electrochemical detection [24,79,80] 
Microscopy [48,80,81] 
Chromatography [3,80] 
Electrophoresis and Magnetophoresis [3,75] 
High definition cameras [24] 
Color change (pH) [28] 
Light scattering [76] 
Ionization Spectroscopy  [80] 
Filtration [75] 
Immuno-agglutination  [76] 
Potentiometry [24] 
Trans-epithelial resistance  [24] 
Acoustic techniques [75] 
Photoacoustic Tomography [44] 
Force transducers [24] 
Flow cytometry [82] 
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The integration of sensors in OoC systems provides an additional advantage over animal and human 
models as electrophysiological signals can be collected and analyzed on real-time[28,58]. This allows the 
quantification of cellular metabolites and study their evolution in front of external stimuli [53]. 
Furthermore,  the functionality of tissues, cells or even intracellular organelles can be tracked [80].  
The main challenge of these measuring systems is to properly assess drug concentration changes and 
physiological responses by employing low sample quantities at low flows and with high dynamism, in a 
heterogeneous and complex-composition environment with the presence of salts, sugars and proteins, 
among others [3,28,53,80]. Aside from the selection of an appropriate analytical technique, an integrated 
OoC system requires the development of specific computer systems dedicated to analyze and integrate the 
measured signals [76,83]. 
OoC systems production 
3D Printing 
One of the major technological contributions for the development of OoCs is the 3D printing. This 
technique allows the construction of the desired architecture, communication channels and functional 
structures with cells and polymeric materials [28,44,57], which makes it possible to control specific 
conditions by modelling mechanical features [7,28,60]. The support structure is made of polymeric 
materials that must accomplish three main characteristics: biocompatibility, easy to shaping and 
transparency. The most commonly used polymer for this purpose is polydimethylsiloxane (PDMS) [1,84]. 
Four different techniques can be used to form OoC by 3D printing: micro-extrusion, stereolithography, 
inkjet bioprinting and laser bioprinting [1,28]. 
In micro-extrusion, a continuous flow of small drops of bio-ink (polymer and cell suspension) is 
generated and pressed out from a small opening whose movement is precisely controlled by a 
computerized system. Although this technique allows the use of bio-inks with complex compositions and 
high viscosity, cell viability could be reduced [1,28,57]. Micro-extrusion is one of the most used techniques 
for the formation of OoC due to its low cost, however, it shows limitations in terms of texture creation and, 
thus, it is not suitable for the elaboration of complex structures in heterogeneous OoC systems [58]. 
Stereolithography creates a liquid pattern that is later polymerized using a laser or ultraviolet (UV) light. 
In this technique, cell viability may be affected due to the length of time of the process and the use of 
intense radiation [28,57,60]. However,  by using stereolithography, vascularized channels can be integrated 
and  hydrogels can be introduced in an easier way [57]. 
In the inkjet bioprinting technique, drops of a non-viscous bio-ink are released into a polymeric 
substrate obtaining a rapid formation of structures by using a low-cost process. There is, however, a lack of 
precision in the direction of the drop and in the control of the viscosity, which makes the construction of 
complex designs difficult [28,85]. 
Finally, laser bioprinting uses a laser beam to push a gelled solution of cells onto a substrate. This 
technique offers high precision in tissue production and a large variety of materials can be used. However, 
cells viability can be affected by the high temperatures produced by the laser during the long processing 
time  [1,58]. 
Cell lines obtention 
The correct selection of biological sources for the production of cellular tissues is a key factor to obtain a 
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greater similarity between OcCs and human tissues. The choice of the source will depend on the organ and 
the genetic background aimed to be studied [2,26,42]. Both primary tissue cells and immortalized lines can 
be used for these purposes, although the latter may show more difficulties performing the physiological 
functions of primary cells [42].  
Numerous authors have cited the use of induced pluripotent stem cells (iPSCs) for regenerative 
medicine, drug discovery and disease modelling [2,3,5,42,74,86–91]. These cells show an extraordinary 
organizational capacity that allows them to be modelled to any physiological or pathological condition 
[2,62,74,86]. Figure 3 shows an outline of iPSCs preparation from various sources by using different 
reprogramming methods, including CRISP-Cas9 genome editing [92].  
The integration of iPSCs in an OoC can be a useful tool for personalized medicine. These kind of cells 
have a great capacity to induce genetic variability [65,90] and make it possible to execute specific 
pathological evaluations, which cannot be performed through current alternatives [2,5]. Musah et al. 
established protocols to differentiate iPSCs into mature-functional podocytes and built a human glomerulus 
in a chip with the aims of nephrotoxicity screening, therapeutic development and the study of kidney 
development and renal impairment [87]. Smith et al. highlighted methods to produce iPSC-derived 
cardiomyocytes for efficacy/toxicity screening and modelling of cardiac diseases [65]. Moreover, Wang et 
al. developed liver organoids that showed hepatic functions from iPSCs [89]. In another approach, Vatine et 
al. used patient-derived iPSCs from individuals with neurological diseases to simulate the disorder’s specific 
physiopathology  [74]. 
 
Figure 3. Diagram of iPSC obtainment from i) Fibroblasts, keratinocytes or melanocytes obtained in skin 
biopsy, ii) CD34+ from blood samples, iii) CD133+ from umbilical cord or iv) multipotent cell from adipose 
tissue; iPSC reprogrammed towards pluripotent cells through different induction mechanisms such as: v) 
microRNA delivery, vi) viral transfection, vii) integration vectors or viii) protein transfection. Adapted from 
[40] under terms of the Creative Commons Attribution License. Copyright (2017). 
Applications 
OoCs are currently used in preclinical phases as a complement to animal models and cell cultures [1,3]. 
2D models cannot be used for drug evaluation in terms of metabolic activity, efficacy or systemic toxicity 
[31,42,43,63]. Nevertheless, OoCs have the potential to replace traditional experimental models, as they 
have shown better in vivo/in vitro extrapolation [6,51,93] and potentially represent a more favorable 
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risk/benefit value in drug research and development [18]. These systems present outstanding features such 
as the chance to simulate dynamic multi-organ environment [1,2,81,94] and to replace the use of humans 
in some phases of clinical studies [80]. Tables 3 and 4 summarize some examples of the applications of OoC 
technologies for organs, systems and pathophysiological conditions. The following sections point out 
additional features for some of the most advanced applications with the greatest impact on academic 
production. 
Table 3. Overview of some functionalities and applications of organs or systems on a chip. Modified from [1,2]. 
Organ or 
System 
Main components of the OoC 
functionality 
 Preclinical application References 
Heart - Contractible 3D conformation. 
- Incorporation of structural proteins. 
- Electrical stimulation. 
- Regulated mitochondrial 
distribution. 
 - Simulation of Frank-Starling 
mechanics in cardiomyocytes. 
- Demonstration of auxotonic 
contractions. 
- Cardiotoxicity tests. 
- Study of physiological phenomena 
involved in cardiac functioning. 
[2][4][6][7][11][18] 
[21] [44][71][70] 
[65] [82] [84][95] 
[96] 
Kidney - Barriers formation. 
- Permeability modulation with 
different types of proteins. 
- Generation of structural proteins. 
- Functional assessment under 
mechanical stress conditions. 
- Separation of tubular flow and 
interstitial fluids. 
 - Selective filtration in kidney models. 
- Simulation of type II diabetes 
mellitus nephropathy. 
- Evaluation of drug-induced 
nephrotoxicity. 
- Research on the physiological role of 
specific proteins. 




Lung - Simulation of the alveolus/capillary 
interface. 
- Modulation of cell permeability. 
- Presence of intercellular proteins. 
- Simulation of air-water interfaces 
with or without the presence of 
airflow. 
 - Breathing simulation using cyclic 
mechanical stress. 
- Evaluation of resistance mechanisms 
in lung cancer. 
- Lung proteins study. 
- Metabolism of drugs. 
- Systemic toxicity studies. 
[1][13][18][21][29] 
[42][52][54][71] 
[99][100] [101]  
Gut - Differentiation of the intestinal 
epithelium. 
- Reproduction of peristalsis. 
- Incorporation of extracellular 
proteins. 
- Reproduction of intracellular and 
paracellular transport. 
 - Microbiota interactions studies. 
- Pathogenic bacteria models. 
- Study of viral infections. 
- Simulation of barrier function loss. 







Liver - 3D cultures with specific liver 
substructures. 
- Kupffer cell incorporation.  
- Incorporation of structural proteins. 
- Secretion and production of high 
levels of urea and albumin. 
- Enzymatic activity.  
- Production of bile and formation of 
gallbladder. 
 - Drug metabolism studies. 
- Hepatotoxic effect of drugs and 
toxicity effects on other organs 
(including the influence of liver 
metabolites). 
- Glycogenesis studies (and inhibition 
by drugs). 









- Blood-brain barrier (BBB) formation 
in the presence of astrocytes and 
neurons, and with modulated cell 
permeability. 
- Formation of tubular vessels. 
- Structural protein incorporation. 
- Brain folding. 
- Replication of the neurovascular 
unit. 
 - Study of neurodegenerative 
diseases. 
- Inflammation studies by 
lipopolysaccharide endotoxins or 
others. 
- Study of the influence of drugs in the 
prenatal period. 
- Determination of permeability of 
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Table 3. Continued… 
Organ or 
System 
Main components of the OoC 
functionality 
 Preclinical application References 
Placenta - Formation of the placental barrier. 
- Permeability modulation for high 
molecular weight proteins. 
- Division of fetal and maternal 
chambers with fluid flow. 
- Transfer of nutrients and glucose to 
fetal compartments. 
- Evaluation of placental responses. 
 - Simulation of drug transport across 
the placenta using cancer-derived 
cells. 





- Creation of adipose spheres that 
simulate adipose tissue in vivo. 
- Vascular-adipose tissue interface. 
- Fatty acid absorption. 
 - Glucose uptake studies. 
- Obesity models. 
- Development of cell retention 
methods. 
[1][96][102] 
Retina - Retinal pigment formation. 
- Development of the epithelium-
choroid structure.  
- Presence of structural proteins. 
 - Pathologies models.  
- Reproduction of imaging processes. 
[1][62][112][113] 
Muscle - Contractile units through chemical 
or electrical stimuli. 
 - Evaluation of the effect and toxicity 
of drugs. 





Immune system [50,71], bone [116,117], breast tissue [118,119], pancreas [120,121], bladder, 
reproductive tract [104], skin [13]. 
Heart-on-a-chip 
Cardiotoxicity is one of the most common causes of drug failures in phase I clinical trials [13], 
highlighting the necessity of more accurate prediction models for a preclinical screening. An interesting 
number of OoC models simulating the human heart have been developed with different levels of 
complexity. Its main application is centered on the evaluation of the contractile and rhythmic functions 
[6,7,13,18,44,122]. The OoC application for heart reproduction can be a powerful tool in the preclinical 
evaluation of a drug, as it allows to connect the heart with the lungs and the liver and to detect toxic 
reactions that may be absent when the drug is assessed in an isolated tissue [1,11,65].  
Schroer et al. published a work focused on contractile characteristics and parameter determination for 
personalized cardiac cell tissues [95]. The heart-on-a-chip developed by Abulaiti et al, (figure 4) allowed the 
evaluation of heart tissue function and visualization of cardiac micro-tissue kinetics by monitoring the 
displacement of fluorescent particles incorporated within one of the device’s compartments through 
fluorescence microscopy, flow cytometry and high resolution cameras  [82]. 
Kidney-on-a-chip 
The kidney is the main organ for hemofiltration, it is involved in waste excretion and it is indispensable 
for homeostasis. Therefore, the study of the renal function by using OoC can be a very interesting tool for 
drug development and for the determination of the systemic safety profile of drugs [2]. The greatest 
challenge in developing functional kidneys-on-a-chip is the simulation of the tubular structure with a 
sophisticated control of the physical parameters involved in the glomerular filtration [1,2,87]. The 
introduction of an on-line renal function detection unit in the OoC allows compounds at very low 
concentrations to be detected in the system [1]. 
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Figure 4. Heart-on-a-chip for the evaluation of physiological parameters. A) Device diagram and structure. 
Graphs B) and C) respectively show the effect of two different isoprotenol concentrations on the heart rate 
and the magnitude of contractile displacement, compared to no treatment values. Adapted from [82] under 
terms of the Creative Commons Attribution License. Copyright (2020). 
Some examples of this technology can be found in the work of Yin et al, who developed a kidney-on-a-
chip device for drug screening and nephrotoxicity assessment (figure 5). They achieved tissue 
differentiation and functionality by growing the two cell cultures on opposite membranes, and evaluated 
the cell growth and viability using fluorescent markers [97]. On the other hand, Jang et al. built a system for 
drug transport and nephrotoxicity assessment in preclinical phases that mimicked key functions of the 
human kidney proximal tubule. The chips architecture exposed cell layers to a fluid shear stress similar of 
that found in living kidney tubules, resulting in an enhanced epithelial cell polarization, differentiation and 
function compared to traditional Transwell culture system [98]. Wang et al. developed a kidney-on-a-chip 
for the study of virus pathogenic mechanisms inducing renal infections, which allowed in-line cell 
characterization using confocal imaging and scanning electron microscope imaging [45]. 
Lung-on-a-chip 
Modern OoC systems are inspired by the pioneering development of a lung-on-a-chip. The main 
challenges for an accurate lung function are the generation of biomechanical ventilation, reproduction of 
lung mucosa  and the capability to overcome the possible prothrombotic interference and the rigidity of the 
simulated lung tissue [1,13]. Stucki et al. developed a system that enables the imitation of the alveolar 
parenchyma and that can produce a mechanical stretching that mimics the breathing mechanism using a 
pneumatic micro-diaphragm. They demonstrated that the mechanical stress affects the epithelial barrier 
permeability [99], which id something to consider when manufacturing other lung models reproducing 
somehow this kind of mechanical stress. Felder et al. studied wound healing recreating an alveolar 
epithelium on a chip also including mechanical strain with the incorporation of an ultra-thin elastic 
membrane (figure 6). This device used immunofluorescence microscopy and scanning electron microscopy 
for the evaluation of test outcomes [100]. The lung-on-a-chip developed by Asad et al. incorporated on line 
detection of pH and trans-epithelial electrical impedance, as well as a microscope that allows visual 
monitoring due to the chip’s transparency [101]. 
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Figure 5. Kidney-on-a-chip device for drug screening and nephrotoxicity assessment. A) Schematic 
representation of the chip’s two chambers. B) Diagram of the complete device including: the chip and the 
temperature and the flow control device. Adapted from [97] under terms of the Creative Commons 
Attribution License. Copyright (2020). 
Gut-on-a-chip 
The small intestine has important functions associated with drug absorption and the immune system 
[2,7]. Applications for OoC-gut models include pharmacodynamics, pharmacokinetics and physiological 
studies, and are frequently linked with the use of CaCo2 cells. These gut-on-a-chip models enable to 
investigate the way how the tissue-microbiota interrelationship can affect the nutrient absorption in the 
gut, and allow the study of the signaling between gastric and intestinal cells [1,54,72,103]. OoC-gut models 
have also been used to evaluate the mucus formation, accumulation and impact on intestinal functionality 
[31,72].  
Peters et al. highlighted the importance of in vitro testing to assess gastrointestinal safety [54]. In 
another approach,  De Haan et al. monitored enzymatic digestion of milk using a microfluidic chip and 
demonstrated the importance of adjusting and correlating digestion times at physiological conditions on 
OoC [69]. Sailer et al. built a gut-on-a-chip from patient-derived intestinal subepithelial myofibroblasts, 
which incorporated growth factors and controlled physiological conditions that showed angiogenic 
properties under simulated perfusion (figure 7) [105].  The gut-on-a-chip also can be found coupled with 
other organs, such as the liver, which allows to study the absorption and metabolism of drugs [51]. 
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Figure 6. Mimicking of breathing mechanics. Schematic representation of A) the movement of the diaphragm 
leading to the lungs expansion during inhalation and B) the imitation of this motion by a mechanical 
microdiaphragm used in lung-on-a-chip devices. Reproduced from  [100] under terms of the Creative 
Commons Attribution License. Copyright (2019) 
 
 
Figure 7. Gut-on-a-chip (GOC) formed by two channels separated by a thin membrane with perfusion 
vasculature on the lower channel. Adapted from [105] under terms of the Creative Commons Attribution 
License. Copyright (2020). 
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Liver-on-a-chip 
The liver plays a crucial role in the drug metabolism and the detoxification of the body. Therefore, it is 
another important organ to take into consideration during the development of new drugs and their effects 
in the other parts of the system [2,11,21,89]. Liver cells grown under 3D conditions are more viable, 
functional and reproducible than those cultured in 2D [2,108]. Liver-on-a-chip models associated with other 
tissues or organs, such as the intestine, may allow to obtain first-step metabolism profiles closer to those 
that could be acquired through traditional cell cultures [1,3,89]. 
Jia et al. described a 3D hepatic system for liver injury studies by controlling hepatocyte viability, 
function, morphology and polarity, and thus, maintaining the tissue morphology, mRNA expression, bile 
secretion and a better cell viability compared to other types of cell cultures. They controlled the 
morphology encapsulating the cell culture inside a alginate hydrogel (figure 8A) [43]. Freyer et al. built an 
OoC model for hepatotoxicity testing, highlighting the importance of the control and monitoring of 
chemical physiological parameters (such as lactate production and ammonia release) (figure 8B). They 
validated the OoC by performing a paracetamol hepatotoxicity determination, which included a histological 
and immunohistochemical evaluation of the damage. They also stablished the need of modifications of the 
OoC to include non-parenchymal cell types at physiological ratios and the creation of defined oxygen 
gradients in order to increase the system’s sensibility for further toxicity studies [107].  
On another approach, Kostrzewski et al. prepared a 3D culture on a plate from primary cells that 
showed positive progression on fatty liver recovery by using known anti-steatosis compounds. This model 
showed adipokine expression and metabolic responses similar to those seen in clinical non-alcoholic fatty 
liver disease. The chip is not designed for on-line quantifications and most of the analytical determinations 
had to be made after removing the microtissues from the chip [108]. As well as the heart or the intestine, 
the liver has been studied in multiorgan chips to investigate systemic effects, absorption and metabolism 
[51,67,68]. 
Central nervous system-, brain- or blood brain barrier (BBB)-on-a-chip 
It is possible to simulate physiological and pathological mechanisms of the central nervous system (CNS) 
in an OoC [2,88]. These models can be very useful considering the complexity of the human brain, which 
makes it difficult to study the CNS in animal models or 2D cultures [13].The blood-brain barrier plays a vital 
role in homeostasis and it is the main limitation for the administration of drugs in the brain [109]. The 
development of integrated systems reproducing the barrier properties and modelling inter-individual 
variation [2,15,74] makes it possible to assess whether a drug designed to treat a neuro-related disease can 
actually reach its therapeutic target [13,78].  
Adriani et al. were able to develop a chip with neurons and astrocytes that showed adequate 
morphology, growth and vascular function, identifying the opportunity to include other types of cells such 
as pericytes and microglia, which increased the model’s potential to be used for neurovascular studies and 
too assess drug effects on brain neural function [48]. The brain endothelium created from primary patient 
cells by Vatine et al. reproduced complex BBB functions with the potential applications of drug screening 
and personalized medicine, using immunocytochemistry, confocal microscopy, calcium imaging and mass 
chromatography as analytical methods, among others [74]. Tu et al. developed a BBB system that 
incorporated transendothelial electrical resistance (TEER) micro-electrodes to monitor cell growth and 
response in the presence of drugs (figure 9) [123]. 
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Figure 8. Schematic examples of liver-on-a-chip devices. A) Multichannel OoC. Representation of a i) 
microfluidic device with several channels of different compositions for the formation of encapsulated hepatic 
plate structures, and a ii) system of syringe pumps supplying the microfluidic channels of the OoC with 
solutions. Adapted from [43] under terms of the Creative Commons Attribution License. Copyright (2020). B) 
Diagram of a pressure-driven flow control system of a 3D liver bioreactor for hepatotoxicity testing under 
perfusion conditions. Adapted from [107] under terms of the Creative Commons Attribution License. Copyright 
(2018). 
 
Figure 9. BBB-on-a-chip with microelectrodes incorporated. A) Diagram of the main channel. B) Diagram of 
the electrodes and the chip structure. C) Photograph of the integrated system. Adapted from [123] under 
terms of the Creative Commons Attribution License. Copyright (2020). 
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Table 4. Main pathological conditions simulated in OoC systems 
Pathology  References 
Cancer [13–15,23,42,50,63,122,124–127] 
Inflammation [7,128–130] 
Epilepsy [44] [64] 
Alzheimer's disease [64] 








Inflammation-on-a-chip, or immune system-on-a-chip 
OoC can also reproduce complex physiological events or multi-organ functions [7,128]. The 
development of the inflammatory system-on-a-chip enables a better understanding of how immune system 
cells synchronize their activities to fight a disease. The evaluation of the coordinated cellular activities 
related to inflammation could have interesting biological and clinical applications [128]. Autoimmune 
diseases or immunity generated by vaccines can also be assessed by OoC systems [50,71,102]. Sharifi et al. 
developed a system on a chip for modeling the immune response cascade of events during immune cell 
response to implants [130], and Goyal et al. described a microfluidic chip for evaluation of vaccine response 
that was able to obtain antibodies and can be useful for immunotherapy candidate selection [130]. 
Gopalakrishnan et al. worked on a real-time continuous monitoring chip (using microscopy and 
fluorescence) for studying cellular migration and organization during inflammatory processes in response to 
simulated cytokine gradients (figure 10) [131]. 
 
Figure 10. Microfluidic device allowing cell migration. A) Simulation of an in vivo scenario with the chip 
construction. B) Schematic of the device’s manufacture by soft lithography. Reproduced from [131] with 
permission from The Royal Society of Chemistry. Copyright (2015). 
Cancer-on-a-chip 
Cancer models in mice have resulted in countless treatments to cure cancer in the animals, although 
they present an alarming difficulty to transfer these results to humans. OoC systems provide the possibility 
to study the physio-pathological mechanisms and the resistance reactions in an environment almost 
identical not only to human disease but to the specific individual. Therefore, these systems can open the 
door to many treatments against cancer [13,14]. 
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Scientists have been able to modulate through OoC devices phenomena such as metastatic cells 
migration, tumor growth or even drug resistance [124,132]. Moreover, potential therapeutic targets and 
possible chemical markers have been identified in preliminary research based on OoC [15]. Nguyen et al. 
used an OoC model to demonstrate pathogenic mechanisms involved with the endothelial changes 
observed in pancreatic cancer, as well as to identify chemical mediators of these phenomena (figure 11) 
[125]. Shuford et al. used primary patient tissue on a chip for the prediction of patient-specific response 
before clinical treatment in ovarian cancer [126]. Choi et al. designed a device with the microarchitecture of 
breast carcinoma to be used as drug screening platform. They validated the screening capacity using it to 
evaluate efficacy and toxicity of paclitaxel [127]. 
Body-on-a-chip or human-on-a-chip for ADME evaluation and preclinical development 
OoCs can assembly multiple tissues and simulate the systematic functionality of the human body. As 
long as each organ shows the most relevant functions associated with the pharmacokinetic phenomena to 
be studied, these systems have the potential to determine the pharmacokinetic profile of drugs 
[7,10,13,42,50,102]. The processes of absorption, distribution, excretion and metabolism (ADME) can be 
simulated from various routes of administration and, moreover, mathematical models can be applied to 
make real-body predictions [10,27,51,66,132,133]. This approach has been used to evaluate the ADME 
profile of drugs and the appearance of physiological events that cause adverse effects in devices of up to 20 
different tissues [7,10,32]. Furthermore, they can also be used to assess a compound effectiveness 
[13,133]. De Melo et al. developed a heart-liver-skin device for the systemic evaluation of drugs 
administrated topically and for the comparison of acute and systemic toxicity (Figure 2B) [67].   
 
Figure 11.  Pancreatic-cancer-on-a-chip. A) i: image of a pancreatic duct (seeded with pancreatic cancer cells) 
and a blood vessel (seeded with endothelial cells) nested within a collagen matrix that are shown on the right 
image; ii: representation of the cross section of the right image. B) Invasion distance that cancer cells traverse 
within the collagen matrix as a function of time, with and without the addition of human umbilical vein 
endothelial cells (HUVECs). C) and D) Invasion of tumoral cells (green) into the blood vessel (red). E) i: 
invasion of the blood vessel by cancer cells, inducing to the apoptosis (marked in white in ii) of endothelial 
cells. Modified from [125] under terms of the Creative Commons Attribution License. Copyright (2019). 
R. Vargas, A. Egurbide-Sifre and L. Medina  ADMET & DMPK 9(2) (2021) 111-141 
128  
The system developed by Rajan et al. including tissues from the brain, liver, lung, heart and endothelium 
showed metabolizing capacity for prodrug transformation, as well as representativity of cardiac toxicity 
[10]. Marin et al. studied acetaminophen absorption and metabolism with an intestine/liver micro-
physiological system demonstrating the potential of these kind of systems for pharmacokinetic profiling of 
drug substances [51]. The cardiotoxicity of the main compound and the metabolites was evaluated with an 
OoC device by Oleaga et al., who developed a model that can be used in preclinical evaluation and for 
chronic studies [11]. Maschmeyer et al. proposed one of the first devices to integrate intestine, liver, skin 
and kidney organoids for ADME profiling, and repeated dose systemic toxicity testing of drug candidates, 
which was sustainable throughout 28 days [134]. The system of fluidically coupled vascularized chips 
proposed by Herland et al. allowed modeling the pharmacokinetics of orally and intravenous administered 
drugs. Their arrangement was able to couple with robotic pumps, chips that represent the gut, liver, kidney, 
and bone marrow, and presented an arteriovenous fluid-mixing reservoir. They obtained pharmacokinetic 
results similar to previously reported clinical data [135].  
One of the most important challenges in the body-on-a-chip development is the proportional replication 
of organs in terms of size, blood flow and metabolic rates. However, in many cases, these proportions are 
still unknown for the human body  [7]. Another challenge of these OoC devices is that they represent a 
small number of cells, and their intercommunication substances undergo under significant dilution 
conditions [42]. 
Nearly a 70 % of drug withdrawals correspond to hepato-cardio toxicity, therefore, it is believed that a 
system that included at least those organs would be enough for a preclinical safety screening [136]. OoCs 
could be used in the future for clinical studies by introducing specific variables needed according to 
personalized groups of patients. Moreover, this might allow studies of pathologies for which there are 
usually not enough candidates for a representative clinical trial [13]. The use of OoC systems in the 
development of new drugs would enable designs based on better physiological understanding and better 
candidate screening [86]. This would lead to an increase in drug development efficiency by reducing costs 
(up to 25 %) and time for the experimental phases [9,18,29], lowering the risk for patients and raising the 
investment in new drugs production [13]. This could increase the number of new discoveries and reduce 
their prices, benefiting, therefore, the health systems at various levels [9,18,20,71]. 
Challenges and perspectives 
In order to exploit the full potential of OoC systems and make them become a validated alternative, 
several physical, physiological and regulatory challenges must be overcome. The first step to obtain 
sophisticated and accurate OoC with a minimum functional unit [13,133] is to have a deep knowledge of 
the organ’s physiology, the cellular metabolism and all pathological mechanisms that can affect the organ 
[31,44,50,53]. Table 5 shows the main challenges or advances required in the manufacture of OoC systems 
for some specific organs. 
Table 5. Main challenges for the improvement of some specific organ-on-a-chip systems: Modified from [1,7]. 
Organ Main challenges 
Kidney Formation of glomeruli with podocytes and entangled proximal tubules. 
Lung Generation of biomechanical ventilation without assistance. Further studies with 
inflammatory and immunological processes and tumors. 
Heart Establishment of validated studies for reproducible cardiotoxicity with various 
drugs. 
Gut Deepening knowledge of mesenchymal-epithelial interactions. 
Placenta Modelling with primary cells. 
Adipose tissue More knowledge of the functioning of brown fat in adipose tissue. 
Brain Standardization and reproducibility of brain organoids. 
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As a field that influences a wide spectrum of disciplines [22], OoCs require significant advances in the 
availability and the implementation of the newest trends from the scientific areas related to their design, 
development, application and production. Overcoming the individual challenges is the key for translating 
OoC to cost-effective and sustainable implementation. We briefly introduce some of those relevant 
challenges, however, more insight into each research area can be found on specific reviews developed for 
this purpose, which can be found elsewhere [33–41,137,138].  
Challenges in fluid mechanics 
Microfluidics are essential for the reproduction of the organ’s conditions in an OoC. The use of external 
systems is critical [73], as well as the 3D arrangement of the microchannels. Many of the current devices 
present a gravity-mediated flow distribution [7,11], however, the development of better microfluidic 
control systems is essential to improve the reproduction and to control the microflows that generate more 
bio-relevant conditions within the chips [42,73]. 
The development of microfluidic is, perhaps, the most important driver in the progress to more 
complex, robust, significant and scalable OoCs. For example, HTS using OoC devices requires improvements 
in microfluidics that allow a better controlled perfusion, sampling and cell injection [18,139], while on the 
other hand, stem cell’s experimentation, production and analysis requires high level of microenvironmental 
control [140]. Chips with integrated micro pumps and, with structural and mechanical considerations that 
allow cell circulation and passive flow control are some of the microfluidic topics with more progress in the 
past years   [41]. 
 Challenges on cell availability 
Physiological reproducibility of OoC mainly depends on the cells that are employed to build them. Cell 
availability challenges in OoC are the same restrictions than those related to cellular tissues: limited access 
to primary cells and possible dysfunction of immortalized cells [7,42]. To have different cell culture types in 
the same environment brings to an extra difficulty, which is shared with regenerative medicine techniques 
[28,90]. Obtaining reproducible tissues, suitable for application in OoC systems, requires the development 
of more and better techniques for the culture, maturation and differentiation of pluripotent cells, as well as 
the standardization of the obtention of protocols [5,55,90]. 
Major breakthroughs in this field include relevant experimentation on novel and standardized methods 
to obtain and differentiate stem cells into functional organ models [141–143], and the continuous efforts 
for the development of a blood substitute, a representative universal cell medium for OoC [41]. 
Challenges in materials engineering 
In this area it is required to develop materials that accomplish all –or most of–  the application criteria in 
an OoC, such as plasticity, elasticity, transparency, biocompatibility or versatility [7,63]. These materials 
must be inert to the drugs to evaluate [44,75] and exhibit easy printing, while achieving adequate mimicry 
with living tissues [28]. The materials that are currently used do not meet all the requirements 
simultaneously. For example, PDMS is one of the most widely used materials to manufacture OoC due to its 
versatility and biocompatibility, nevertheless, it has shown a tendency to absorb small molecules, such as 
many of the drugs evaluated [10,18,30,144]. Therefore, the discovery of intelligent materials that can 
change their shape and reactivity in front of different stimuli, known as four-dimensional printing, is a 
promising strategy for the future OoC [58]. Recent advances include the introduction of a variety of 
biocompatible and thermoplastic materials that are presumably more suitable for large scale 
manufacturing processes [41]. 
R. Vargas, A. Egurbide-Sifre and L. Medina  ADMET & DMPK 9(2) (2021) 111-141 
130  
Challenges in measurement systems 
The evolution of OoC requires an improvement in the development of specific electrodes and/or 
biosensors [7,28] with high performance, high sensitivity and high specificity [18,53,80]. The high sensitivity 
is required due to the low amount of metabolic secretions [3]. Moreover, it must be possible to measure 
the tissue response at many other levels, as well as the concentration variations of the specific substance 
[42].  Therefore, OoC systems must have the ability to detect small non-lethal changes that affect 
functionality at the cellular level [7,41]. More feasible, adaptable to HTS and scalable bio-assays also 
require microfluid regulators such as valves, pumps, mixers and other functional elements to get cell 
perfusion with fresh media and assay reagents [139]. These systems must allow non-invasive parallel 
measurements, automation and flexibility in order to fit HTS programs used by Big Pharma companies to 
evaluate their compound libraries [4,18,29,41,75]. 
Commercially available micro-sensors of thermos responsive materials and electrodes, as well as optical 
methods for pH and oxygen determination, have been successfully incorporated to OoC devices, [41] in 
addition to several prototypes of organic biotransistors [145]. In the particular case of a BBB-on-a-chip, 
TEER has become the most popular online sense method. But other alternatives such as physical sensors, 
with the ability of measuring small concentrations of metabolites, and a variety of biosensors, bioreceptors 
that generate an electric signal after binding a biological target, have been proposed (figure 12) [146]. 
Software-driven analyses of optical recordings have been described for several cellular functions such as 
the heart rate [82], which can be used to evaluate other related muscular functions. 
 
Figure 12. Biosensors and sensors on BBB-on-a-chip transducing signals to a PC or mobile interface. 
Reproduced from [146] under terms of the Creative Commons Attribution License. Copyright (2019). 
Challenges on industrial scale production 
There are many OoC prototypes that have been presented only as a pilot test at laboratory level. The 
success of an OoC system in solving real problems depends on how rigorously it fits the real model, but 
furthermore, on how easily it can be transferred to industrial production. In many cases, the OoC prototype 
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is obtained through an effective 3D printing technique, but it is inefficient for large scale due to the low 
speed at which the structures are created [7,11,28].  
Low cost or reusable materials could lead to a more widespread use of OoC in early stages of drug 
discovery [143]. Massive parallelization and automation of OoC systems are among the biggest challenges 
to overcome in order to meet industrial requirements of HTS [18]. The work of Ramadan and Zourob [137] 
contains a comprehensive review not only of the main challenges, but of specific strategies to solve them, 
trends and examples of the main industrialization activities of some of the developing OoC systems. 
The more sophisticated an OoC becomes, the more it needs to be controlled, which increases its cost 
and limits its usege. To ensure reproducibility of OoCs [49] specific tests must be developed in parallel for 
the quality control of the devices [133]. Besides any limitation, the number of commercially available OoC 
devices, new start-up companies and patent applications have considerably increased these last years 
[136]. 
OoC validation 
The validation of OoC systems is particularly important for regulatory agencies to accept them as clinical 
and experimental alternatives, especially in toxicity trials [13,42,43]. So far, many OoC developments 
correspond to isolated publications with a lack of standardized protocols for operation, data collection and 
analyses [63]. Direct comparisons require specific clinical studies and long-term gathered data. Thus, many 
OoC system improvements are performed in collaboration between academia, industry and regulatory 
authorities [7,50]. Regulatory agencies, academia and several companies have been conducting efforts to 
establish industrial standards and validation guidelines for OoC technologies [136]. The replication of 
already-conducted trials executed with approved products and the comparison of their results with the 
results obtained with approved assays is one way of achieving the acceptance of OoC systems as alternative 
methods for pre-clinical –or even clinical– studies [7,136].  OoC could be used to replicate cases of clinical 
studies in which severe adverse events were not detected pre-clinical stages and drugs had to be 
withdrawn from the market, therefore, it could be determined if this technology has a greater or equal 
predictive capacity [44]. 
Conclusions 
There is growing evidence that OoC systems are a novel tool that will facilitate the search, development 
and evaluation of new drugs. These systems show characteristics of reproducibility, adaptability and 
versatility that make them a potential alternative to the use of experimental animals. 
OoCs are an evolution of 2D cell cultures, thus maintaining some of the characteristics of cell tissue 
evaluations. However, these new systems overcome many of the conventional cell cultures weaknesses, 
such as the poor extrapolation to an entire organism. OoC simulate the real microenvironment and the key 
functional aspects of organs at a microscopic scale. This enables the study of drugs as well as the 
investigation of physiological and physio-pathological phenomena.  
The construction of OoC requires a deep understanding of the real functionality of the tissue/organ to 
be studied and mimicked. In many cases, this knowledge is limited, thus leading to a synergy between the 
research in physiology and the development of OoCs. These systems could –scientifically and financially– 
promote the development of new drugs. Risk reduction could revolutionize the way big pharmaceutical 
companies focus their development efforts, as well as the approach of how clinical and preclinical studies 
are conducted.  
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OoC's progress efforts must converge on the development of systems with enough representativeness, 
reproducibility, scalability and suitability for HTS, which maintain at the same time reasonable production 
and implementations costs. Although science is far from being able to mimic at 100 % the human body in a 
laboratory, any advance will increase the predictive potential of OoC systems and will provide innumerable 
benefits for new drugs development. 
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